Overwhelmed by the cannabis earnings reports? Here's the metric that Jim Cramer watches.
Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.
Matthew Cheslock, an equity trader with Virtu Financial, discusses Lyft's roadshow and the competition between Lyft and Uber, whether or not the Federal Reserve will be even more dovish during their March meeting and why investors should keep an eye on FAANG.
Tech is leading the pack. Here's what to keep an eye on in this sector.
Gary Cohen says that tariffs are impacting the American consumer, but Jim Cramer thinks that the tariffs haven't hit American Investors just yet.
Jim Cramer has some advice for investors keeping an eye on companies that are cutting costs to be healthy.
Jim Cramer breaks down why investors should be careful about paying more for the same earnings estimate.
Be wary of rallies based on hope, warns Jim Cramer.
Nelson Peltz may be making Aurora relevant in today's headlines, but it's who invests money in the companies that counts, according to Jim Cramer.
Jim Cramer's got some thoughts on cannabis and whether or not it's time to break up big tech.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.